MIRA Pharmaceuticals (MIRA)
Develops oral small-molecule candidates for pain, obesity, and addiction-related disorders.
Something off on this page? Send us feedback.
Develops oral small-molecule candidates for pain, obesity, and addiction-related disorders, with Ketamir-2 in human testing and MIRA-55 and SKNY-1 preclinical. The pre-commercial model relies on licensed IP, external providers, further regulatory progress, and financing.
Develops oral small-molecule candidates for neuropathic and chronic inflammatory pain, obesity, and addiction-related disorders. Ketamir-2 has completed dosing in healthy volunteers under an active U.S. IND; MIRA-55 and SKNY-1 remain in preclinical, IND-enabling work.
Operates as a small, pre-commercial sponsor with no approved products or product revenue, using consultants and outside providers for clinical, manufacturing, regulatory, accounting, and scientific work. Licensed intellectual property gives it worldwide development and commercialization rights where relevant patent rights exist.
Further studies, regulatory approvals, financing, and its MIRALOGX licenses determine the path to commercializing or sublicensing the programs.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.1M · Total debt $0 · Total assets $8.2M · Shareholders' equity $8.2M
- Revenue
- $0
- Operating income
- −$1.2M
- Net income
- −$1.2M
No dividends on record.
| Institutions26 holders · as of Mar 31, 2026 | 5.11% | 2.15M shares | |
| Insiders2 holders · as of Oct 3, 2025 | 8.45% | 3.55M shares | |
| Otherremainder | 86.44% | 36.32M shares |
42.02M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Erez AminovInsiderdirector, officer: Chief Executive Officer | 8.40% | 3.53M | Form 4filed Oct 3, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 1.65% | 693,912 | 13Fas of Mar 31, 2026 |
Cross Staff Investments IncInstitution | 0.86% | 359,401 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.69% | 290,890 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.40% | 169,483 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Eli Lilly
Dominant obesity franchise with Zepbound and oral Foundayo.
- Novo Nordisk (ADR)
Wegovy franchise leads obesity care, including an oral option.
- Artelo Biosciences
Closest clinical-stage rival in non-opioid CIPN therapy.
- Viking Therapeutics
Late-stage oral and injectable obesity candidate VK2735.
- Scilex
Commercial non-opioid therapies for neuropathic and chronic pain.
- Achieve Life Sciences
Late-stage nicotine-dependence therapy for smoking and vaping cessation.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MIRA Pharmaceuticals | $0.8303 | −4.01% | $35.7M | — | — | — | — |
| Eli Lilly | $1,165.61 | +0.54% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novo Nordisk (ADR) | $47.58 | +1.76% | $207.69B | 11.5 | 18.8 | 4.1 | +0.0% |
| Artelo Biosciences | $6.68 | +1.83% | $2.5M | — | — | — | — |
| Viking Therapeutics | $33.40 | −0.30% | $3.91B | — | — | — | — |
| Scilex | $5.34 | −1.11% | $45.4M | — | 57.2 | 1.4 | −22.8% |
| Achieve Life Sciences | $8.47 | −0.18% | $870.5M | — | — | — | — |
| Median | 25.2 | 28.4 | 4.1 | +0.0% |